The estimated Net Worth of Michele Ilene Korfin is at least $982 millier dollars as of 14 June 2019. Ms. Korfin owns over 5,000 units of Tyme Technologies Inc stock worth over $1,550 and over the last 6 years she sold TYME stock worth over $0. In addition, she makes $980,447 as Chief Operating Officer at Tyme Technologies Inc.
Sign up
Ms. Korfin TYME stock SEC Form 4 insiders trading
Michele has made over 1 trades of the Tyme Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of TYME stock worth $5,150 on 14 June 2019.
The largest trade she's ever made was buying 5,000 units of Tyme Technologies Inc stock on 14 June 2019 worth over $5,150. On average, Michele trades about 556 units every 0 days since 2019. As of 14 June 2019 she still owns at least 5,000 units of Tyme Technologies Inc stock.
You can see the complete history of Ms. Korfin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michele Korfin biography
Michele Korfin serves as Chief Operating Officer of the Company. She has served as the Chief Operating Officer of Tyme since March 2019. She previously served as the Chief Commercial Officer beginning in October 2018. Ms. Korfin has over 20 years of experience in oncology, focused on drug development, product launches, oncology marketing strategy, commercial sales, market access and government affairs. Before joining the Company, from April 2016 to July 2018, Ms. Korfin was the Vice President of Market Access at Kite Pharma, where she oversaw the market access strategy, including payer relations, reimbursement and government affairs for Yescarta®, the first approved CAR-T therapy in lymphoma. Prior to joining Kite, from 2004 to March 2016, Ms. Korfin spent more than a decade at Celgene in a variety of key strategic and operational roles, including head of the oncology sales force and overseeing the global development programs for REVLIMID® in Lymphoma and Chronic Lymphocytic Leukemia (“CLL”). While leading the global development programs for REVLIMID® in Lymphoma and CLL, Ms. Korfin focused on bridging pre-clinical science, translational medicine, clinical development and oversaw the path to successful regulatory approvals. She is also on the board of trustees of BioNJ, an organization that represents the biotechnology industry for New Jersey.
What is the salary of Michele Korfin?
As the Chief Operating Officer of Tyme Technologies Inc, the total compensation of Michele Korfin at Tyme Technologies Inc is $980,447. There are 1 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.
How old is Michele Korfin?
Michele Korfin is 48, she's been the Chief Operating Officer of Tyme Technologies Inc since 2019. There are 16 older and 2 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.
What's Michele Korfin's mailing address?
Michele's mailing address filed with the SEC is C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON, MA, 02021.
Insiders trading at Tyme Technologies Inc
Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian et Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.
What does Tyme Technologies Inc do?
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
What does Tyme Technologies Inc's logo look like?
Complete history of Ms. Korfin stock trades at Tyme Technologies Inc, Gamida Cell Ltd et Organogenesis
Tyme Technologies Inc executives and stock owners
Tyme Technologies Inc executives and other stock owners filed with the SEC include:
-
James Biehl,
Chief Legal Officer and Corporate Secretary -
Michele Korfin,
Chief Operating Officer -
Steve Hoffman,
Chairman of the Board, Chief Executive Officer, Chief Science Officer -
Steven E. Hoffman,
Co-Founder, Chairman & Chief Science Officer -
James Biehl J.D.,
Chief Legal Officer & Sec. -
Dr. Jonathan M. Eckard,
Chief Bus. Officer -
Richard Cunningham,
CEO & Director -
David Carberry,
Independent Director -
Donald Degolyer,
Independent Director -
Gerald Sokol,
Independent Director -
Timothy Tyson,
Independent Director -
Douglas Michels,
Independent Director -
Paul Sturman,
Independent Director -
Jonathan Eckard,
Chief Business Officer -
Giuseppe Del Priore,
Chief Medical Officer -
Barbara Galaini,
Principal Financial Officer, Principal Accounting Officer, Corporate Controller -
Frank L. Porfido,
Chief Financial Officer -
Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
Acting Chief Medical Officer -
Dr. John M. Rothman,
Exec. VP of Product Devel. -
John Zucaro P.E.,
Sr. VP of CMC -
Tommy G Thompson,
Director -
Christine D. Baker,
Director -
John M. Rothman,
EVP, Product Development -
Michael Demurjian,
10% owner -
Ben R Taylor,
President, CFO -
Tornout Jan M Van,
Acting Chief Medical Officer -
Christopher F Brown,
10% owner -
Frank L. Porfido,
Chief Financial Officer -
Richard Anthony Cunningham,,
Chief Executive Officer